Bristol Myers Squibb UK & Ireland in the news

Bristol Myers Squibb earned a Menopause Friendly Honour for achieving accreditation in three regions, demonstrating a global commitment to supporting employees experiencing menopause.

Bristol Myers Squibb has been awarded menopause-friendly accreditation across its UK, US, and Australian operations for its supportive workplace policies and initiatives.

Lynelle B. Hoch leads Bristol Myers Squibb's Cell Therapy Organization, driving the research, development, manufacturing, and commercialization of cell therapies for cancer and autoimmune disorders.

Lynelle Hoch, President of Cell Therapy Organization at Bristol Myers Squibb, leads global cell therapy efforts, leveraging her extensive company experience to advance treatments for cancer and autoimmune disorders.

Ben Hickey returns to Bristol Myers Squibb to lead RayzeBio, an acquired subsidiary developing specialized radiopharmaceutical platforms for oncology.

Employees are participating in a multi-day European cycling event to raise money for cancer charities and demonstrate corporate commitment to patient care.

The Scottish Medicines Consortium approved a combination of nivolumab and ipilimumab for treating advanced colorectal cancer with specific genetic markers.

NICE has recommended nivolumab as an option for neoadjuvant and adjuvant treatment for resectable non-small cell lung cancer with a high risk of recurrence.

Bristol Myers Squibb plans to launch its new schizophrenia drug Cobenfy in the UK at the same price as in the US, amid global drug pricing discussions.

Major pharmaceutical companies are executing mass layoffs and restructuring programs to reallocate billions in savings toward high-growth drug development areas.

The UK's life sciences sector faces significant regulatory and financial challenges, including a revenue cap and a flawed drug pricing deal, hindering investment and the adoption of new medicines within the NHS.

Bristol Myers Squibb's dual immunotherapy Opdivo plus Yervoy received a NICE recommendation as a first-line treatment for a subset of colorectal cancer patients in the UK.

Pharmaceutical leaders are warning that high government payment rates under the VPAG scheme are putting the UK's life sciences growth at risk, leading to a decline in the industry's international competitiveness.

Karen Costello, the new General Manager, is focused on advancing Bristol Myers Squibb's operations in Ireland, enhancing patient access to medicines, and leveraging a $400 million investment in a new sterile drug product facility.

Carrick Group acquired two Irish captives from Bristol-Myers Squibb to expand its non-life legacy business.

Bristol Myers Squibb's Opdualag, an immunotherapy combination, received approval from the Scottish Medicines Consortium for first-line treatment of advanced melanoma in Scotland.

Bristol Myers Squibb's immunotherapy combination, Opdualag, received approval from the Scottish Medicines Consortium for advanced melanoma, offering a new first-line treatment in NHS Scotland.

Guy Oliver joins as General Manager for the UK and Ireland to lead commercial operations and portfolio renewal.

Guy Oliver has been appointed General Manager of Bristol Myers Squibb UK and Ireland to oversee portfolio transformation.

Bristol Myers Squibb UK & Ireland's new Cancer Equals campaign and report highlight significant inequalities in cancer diagnosis and care across the UK, advocating for systemic changes and support for early detection.